Literature DB >> 27086036

The tumor promoting roles of erythropoietin/erythropoietin receptor signaling pathway in gastric cancer.

Weiling Hu1,2, Yu Zhang3,4, Zhinong Jiang5, Lan Wang3,4, Jun Li3,4, Shujie Chen3,4, Ning Dai3,4, Jianmin Si6,7.   

Abstract

Erythropoietin (EPO), binding with its receptor (EPOR), plays an important role in erythropoiesis. EPOR is reported to be expressed in various non-hematopoietic cancers, including gastric cancer. Although recombinant human EPO (rhEPO) has been widely used clinically in anemia patients, it remains controversial whether it would promote tumor progression. In this study, we used siRNA interference method to downregulate EPOR expression to investigate the function of EPO/EPOR pathway in human gastric cancer cells. We found EPOR expressed significantly higher in gastric cancer tissues, and also in most gastric cancer cell lines. RhEPO promoted gastric cancer cell proliferation, migration in AGS cells, and promoted cells from G0/G1 stage to G2/M stage, but had no regulation on AGS cell apoptosis. Downregulation of EPOR expression by siRNA interference in AGS cells resulted in no significant effects on proliferation and invasiveness of the cells, but induced apoptosis (p < 0.05). Xenografted gastric tumor model was used to explore the effect of EPOR-overexpression on gastric cancer cells in vivo. Our result showed that overexpression of EPOR enhanced tumor formation in nude mice (p < 0.01). Our results suggest that EPO/EPOR pathway promotes gastric cancer formation, proliferation, migration, and decreases apoptosis.

Entities:  

Keywords:  Erythropoietin (EPO); Erythropoietin receptor (EPOR); Gastric cancer; Migration; Proliferation

Mesh:

Substances:

Year:  2016        PMID: 27086036     DOI: 10.1007/s13277-016-5053-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  36 in total

1.  Public perception of the risk of blood transfusion.

Authors:  M L Finucane; P Slovic; C K Mertz
Journal:  Transfusion       Date:  2000-08       Impact factor: 3.157

2.  Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models.

Authors:  Benjamin D Hedley; Jenny E Chu; D George Ormond; Michel S Beausoleil; Alexandra Boasie; Alison L Allan; Anargyros Xenocostas
Journal:  Clin Cancer Res       Date:  2011-08-19       Impact factor: 12.531

3.  Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin.

Authors:  E A Dunlop; M J Percy; M P Boland; A P Maxwell; T R Lappin
Journal:  Neurodegener Dis       Date:  2006       Impact factor: 2.977

4.  Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

Authors:  T J Littlewood; E Bajetta; J W Nortier; E Vercammen; B Rapoport
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

Review 5.  Erythropoietin in cancer patients: pros and cons.

Authors:  Mario Dicato; Laurent Plawny
Journal:  Curr Opin Oncol       Date:  2010-07       Impact factor: 3.645

6.  Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients.

Authors:  Thomas Thomaidis; Arndt Weinmann; Martin Sprinzl; Stephan Kanzler; Jochen Raedle; Matthias Ebert; Carl Cristoph Schimanski; Peter Robert Galle; Thomas Hoehler; Markus Moehler
Journal:  Int J Clin Oncol       Date:  2013-03-27       Impact factor: 3.402

Review 7.  Biology of erythropoietin.

Authors:  C Lacombe; P Mayeux
Journal:  Haematologica       Date:  1998-08       Impact factor: 9.941

8.  Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.

Authors:  Michael Hedenus; Magnus Adriansson; Jesus San Miguel; Mark H H Kramer; Martin R Schipperus; Eeva Juvonen; Kerry Taylor; Andrew Belch; Albert Altés; Giovanni Martinelli; David Watson; James Matcham; Gregory Rossi; Timothy J Littlewood
Journal:  Br J Haematol       Date:  2003-08       Impact factor: 6.998

9.  Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer.

Authors:  Gillian Thomas; Shamshad Ali; Frank J P Hoebers; Kathleen M Darcy; William H Rodgers; Malti Patel; Ovardia Abulafia; Joseph A Lucci; Adrian C Begg
Journal:  Gynecol Oncol       Date:  2007-11-26       Impact factor: 5.482

Review 10.  Developments in the therapeutic use of erythropoiesis stimulating agents.

Authors:  Wolfgang Jelkmann
Journal:  Br J Haematol       Date:  2008-05       Impact factor: 6.998

View more
  1 in total

1.  A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders.

Authors:  Monojit Das; Susmita Mondal; Ria Ghosh; Pritam Biswas; Ziad Moussa; Soumendra Darbar; Saleh A Ahmed; Anjan Kumar Das; Siddhartha Sankar Bhattacharya; Debasish Pal; Asim Kumar Mallick; Prantar Chakrabarti; Jayanta Kumar Kundu; Aniruddha Adhikari; Samir Kumar Pal
Journal:  iScience       Date:  2022-08-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.